NASDAQ:ICVX Icosavax (ICVX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$15.31▼$15.3150-Day Range$15.31▼$15.4552-Week Range$4.75▼$16.10VolumeN/AAverage Volume1.22 million shsMarket Capitalization$766.88 millionP/E RatioN/ADividend YieldN/APrice Target$26.50 Stock AnalysisStock Analysis Get Icosavax alerts: Email Address Icosavax MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside73.1% Upside$26.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.20) to ($2.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.99 out of 5 starsMedical Sector774th out of 910 stocksBiotechnology Industry4th out of 8 stocks 3.2 Analyst's Opinion Consensus RatingIcosavax has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageIcosavax has received no research coverage in the past 90 days.Read more about Icosavax's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ICVX. Previous Next 0.0 Dividend Strength Dividend YieldIcosavax does not currently pay a dividend.Dividend GrowthIcosavax does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ICVX. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for ICVX on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Icosavax insiders have not sold or bought any company stock.Percentage Held by Insiders30.59% of the stock of Icosavax is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.59% of the stock of Icosavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Icosavax's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Icosavax are expected to decrease in the coming year, from ($2.20) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Icosavax is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Icosavax is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIcosavax has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Icosavax Stock (NASDAQ:ICVX)Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.Read More Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << ICVX Stock News HeadlinesAugust 2, 2024 | morningstar.comVaxcyte Inc Ordinary Shares 5VAApril 21, 2024 | morningstar.comNervGen Pharma Corp Ordinary Shares NGENSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.March 20, 2024 | markets.businessinsider.comCHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)February 11, 2024 | seekingalpha.comIcosavax: Tender Offer With Contingent Value RightJanuary 5, 2024 | seekingalpha.comIcosavax CVR Seems Fairly ValuedJanuary 2, 2024 | msn.comGuggenheim Downgrades Icosavax (ICVX)December 31, 2023 | businesswire.comICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVXSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.December 24, 2023 | finance.yahoo.comChief Medical Officer Niranjan Kanesa-thasan Sells 11,884 Shares of Icosavax Inc (ICVX)December 18, 2023 | ca.finance.yahoo.comICVX Jul 2024 15.000 callDecember 16, 2023 | finance.yahoo.comInsider Sell Alert: Chief Business Officer Cassia Cearley Sells 8,759 Shares of Icosavax Inc (ICVX)December 13, 2023 | finance.yahoo.comIcosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should KnowDecember 13, 2023 | finance.yahoo.comIcosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the UpgradeDecember 12, 2023 | realmoney.thestreet.comIcosavax just downgraded at Jefferies, here's whyDecember 12, 2023 | msn.comIcosavax deal CVR based on FDA approval for IVX-A12, sales in EU, UK, CanadaDecember 12, 2023 | realmoney.thestreet.comIcosavax just downgraded at William Blair, here's whyDecember 12, 2023 | stockhouse.comShareholder Alert: Ademi LLP investigates whether Icosavax, Inc. has obtained a Fair Price in its transaction with AstraZenecaSee More Headlines Receive ICVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ICVX CUSIPN/A CIK1786255 Webicosavax.com Phone206-737-0085FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$26.50 High Stock Price Target$28.00 Low Stock Price Target$25.00 Potential Upside/Downside+73.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-91,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.06% Return on Assets-39.53% Debt Debt-to-Equity RatioN/A Current Ratio18.06 Quick Ratio18.06 Sales & Book Value Annual Sales$580,000.00 Price / Sales1,322.20 Cash FlowN/A Price / Cash FlowN/A Book Value$5.47 per share Price / Book2.80Miscellaneous Outstanding Shares50,090,000Free Float34,767,000Market Cap$766.88 million OptionableOptionable Beta1.28 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Adam K. Simpson (Age 48)President, CEO, Co-Founder & Director Comp: $855.95kMr. Niranjan Kanesa-thasan M.D. (Age 63)Chief Medical Officer Comp: $641.55kDr. Cassia Cearley Ph.D. (Age 41)Treasurer & Chief Business Officer Comp: $632.15kMr. Neil King Ph.D.Chair of Scientific Advisory Board & Co-FounderDr. David Baker M.D.Ph.D., Co-founder & Member of Scientific Advisory BoardMr. Thomas Joseph Russo C.F.A. (Age 52)Chief Financial Officer Comp: $525.27kMs. Jennifer RaymondSenior Vice President of Technical OperationsMs. Elizabeth Bekiroglu (Age 54)General Counsel & Corporate Secretary Comp: $230.74kMs. Lori StewartSenior Vice President of People & CultureDr. Ami Shah Brown MPHPh.D., Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsStoke TherapeuticsNASDAQ:STOKMonte Rosa TherapeuticsNASDAQ:GLUEActuate TherapeuticsNASDAQ:ACTUKinnate BiopharmaNASDAQ:KNTESeres TherapeuticsNASDAQ:MCRBView All CompetitorsInsidersAdam K SimpsonSold 15,000 sharesTotal: $229,350.00 ($15.29/share)Niranjan Kanesa-ThasanSold 106,373 sharesTotal: $1.67 M ($15.70/share)Adam K SimpsonSold 15,000 sharesTotal: $235,050.00 ($15.67/share)Adam K SimpsonSold 90,000 sharesTotal: $1.39 M ($15.44/share)Thomas Joseph RussoSold 15,183 sharesTotal: $234,729.18 ($15.46/share) ICVX Stock Analysis - Frequently Asked Questions How were Icosavax's earnings last quarter? Icosavax, Inc. (NASDAQ:ICVX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.81. The company earned $1.83 million during the quarter, compared to analysts' expectations of $3.30 million. When did Icosavax IPO? Icosavax (ICVX) raised $150 million in an IPO on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. This page (NASDAQ:ICVX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Icosavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Icosavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.